1887

Abstract

Recombinant measles virus (rMV) vectors expressing heterologous viral membrane protein antigens are potentially useful as vaccines. Genes encoding the mumps virus haemagglutinin-neuraminidase (MuV-HN), the influenza virus haemagglutinin (Flu-HA) or the respiratory syncytial virus fusion (RSV-F) proteins were inserted into the genome of a live attenuated vaccine strain of measles virus. Additionally, in this case rMV with the MuV-HN or the influenza HA inserts, chimeric constructs were created that harboured the measles virus native haemagglutinin or fusion protein cytoplasmic domains. In all three cases, sucrose-gradient purified preparations of rMV were found to have incorporated the heterologous viral membrane protein on the viral membrane. The possible utility of rMV expressing RSV-F (rMV.RSV-F) as a vaccine was tested in a cotton rat challenge model. Vaccination with rMV.RSV-F efficiently induced neutralizing antibodies against RSV and protected animals from infection with RSV in the lungs.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.000523
2016-09-01
2019-09-20
Loading full text...

Full text loading...

/deliver/fulltext/jgv/97/9/2117.html?itemId=/content/journal/jgv/10.1099/jgv.0.000523&mimeType=html&fmt=ahah

References

  1. Albrecht P., Herrmann K., Burns G. R..( 1981;). Role of virus strain in conventional and enhanced measles plaque neutralization test. . J Virol Methods 3: 251–260.[PubMed] [Crossref]
    [Google Scholar]
  2. Bolton D. L., Santra S., Swett-Tapia C., Custers J., Song K., Balachandran H., Mach L., Naim H., Kozlowski P. A. et al.( 2012;). Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates. . Vaccine 30: 5991–5998. [CrossRef] [PubMed]
    [Google Scholar]
  3. Boukhvalova M. S., Prince G. A., Blanco J. C..( 2009;). The cotton rat model of respiratory viral infections. . Biologicals 37: 152–159. [CrossRef] [PubMed]
    [Google Scholar]
  4. Brandenburg B., Koudstaal W., Goudsmit J., Klaren V., Tang C., Bujny M. V., Korse H. J., Kwaks T., Otterstrom J. J. et al.( 2013;). Mechanisms of hemagglutinin targeted influenza virus neutralization. . PLoS One 8: e80034. [CrossRef] [PubMed]
    [Google Scholar]
  5. Cantarella G., Liniger M., Zuniga A., Schiller J. T., Billeter M., Naim H. Y., Glueck R..( 2009;). Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma. . Vaccine 27: 3385–3390. [CrossRef] [PubMed]
    [Google Scholar]
  6. Guerbois M., Moris A., Combredet C., Najburg V., Ruffié C., Février M., Cayet N., Brandler S., Schwartz O. et al.( 2009;). Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160DeltaV1V2 is strongly immunogenic. . Virology 388: 191–203. [CrossRef] [PubMed]
    [Google Scholar]
  7. Kim E., Okada K., Beeler J. A., Crim R. L., Piedra P. A., Gilbert B. E., Gambotto A..( 2014;). Development of an adenovirus-based respiratory syncytial virus vaccine: preclinical evaluation of efficacy, immunogenicity, and enhanced disease in a cotton rat model. . J Virol 88: 5100–5108. [CrossRef] [PubMed]
    [Google Scholar]
  8. Li M., Schmitt P. T., Li Z., McCrory T. S., He B., Schmitt A. P..( 2009;). Mumps virus matrix, fusion, and nucleocapsid proteins cooperate for efficient production of virus-like particles. . J Virol 83: 7261–7272. [CrossRef] [PubMed]
    [Google Scholar]
  9. Liniger M., Zuniga A., Morin T. N., Combardiere B., Marty R., Wiegand M., Ilter O., Knuchel M., Naim H. Y..( 2009;). Recombinant measles viruses expressing single or multiple antigens of human immunodeficiency virus (HIV-1) induce cellular and humoral immune responses. . Vaccine 27: 3299–3305. [CrossRef] [PubMed]
    [Google Scholar]
  10. McLean H. Q., Fiebelkorn A. P., Temte J. L., Wallace G. S.. Centers for Disease Control and Prevention( 2013;). Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). . MMWR Recomm Rep 62: 1–34.[PubMed]
    [Google Scholar]
  11. Mok H., Cheng X., Xu Q., Zengel J. R., Parhy B., Zhao J., Wang C. K., Jin H..( 2012;). Evaluation of measles vaccine virus as a vector to deliver respiratory syncytial virus fusion protein or Epstein-Barr virus glycoprotein gp350. . Open Virol J 6: 12–22. [CrossRef] [PubMed]
    [Google Scholar]
  12. Mourez T., Mesel-Lemoine M., Combredet C., Najburg V., Cayet N., Tangy F..( 2011;). A chimeric measles virus with a lentiviral envelope replicates exclusively in CD4+/CCR5+ cells. . Virology 419: 117–125. [CrossRef] [PubMed]
    [Google Scholar]
  13. Parks C. L., Lerch R. A., Walpita P., Sidhu M. S., Udem S. A..( 1999;). Enhanced measles virus cDNA rescue and gene expression after heat shock. . J Virol 73: 3560–3566.[PubMed]
    [Google Scholar]
  14. Prince G. A., Jenson A. B., Horswood R. L., Camargo E., Chanock R. M..( 1978;). The pathogenesis of respiratory syncytial virus infection in cotton rats. . Am J Pathol 93: 771–791.[PubMed]
    [Google Scholar]
  15. Prince G. A., Potash L., Horswood R. L., Camargo E., Suffin S. C., Johnson R. A., Chanock R. M..( 1979;). Intramuscular inoculation of live respiratory syncytial virus induces immunity in cotton rats. . Infect Immun 23: 723–728.[PubMed]
    [Google Scholar]
  16. Prince G. A., Horswood R. L., Chanock R. M..( 1985;). Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. . J Virol 55: 517–520.[PubMed]
    [Google Scholar]
  17. Radecke F., Spielhofer P., Schneider H., Kaelin K., Huber M., Dötsch C., Christiansen G., Billeter M. A..( 1995;). Rescue of measles viruses from cloned DNA. . EMBO J 14: 5773–5784.[PubMed] [Crossref]
    [Google Scholar]
  18. Ramsauer K., Schwameis M., Firbas C., Müllner M., Putnak R. J., Thomas S. J., Desprès P., Tauber E., Jilma B. et al.( 2015;). Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. . Lancet Infect Dis 15: 519–527. [CrossRef] [PubMed]
    [Google Scholar]
  19. Rennick L. J., de Vries R. D., Carsillo T. J., Lemon K., van Amerongen G., Ludlow M., Nguyen D. T., Yüksel S., Verburgh R. J. et al.( 2015;). Live-attenuated measles virus vaccine targets dendritic cells and macrophages in muscle of nonhuman primates. . J Virol 89: 2192–2200. [CrossRef] [PubMed]
    [Google Scholar]
  20. Sawada A., Komase K., Nakayama T..( 2011;). AIK-C measles vaccine expressing fusion protein of respiratory syncytial virus induces protective antibodies in cotton rats. . Vaccine 29: 1481–1490. [CrossRef] [PubMed]
    [Google Scholar]
  21. Schwarzer S., Reibel S., Lang A. B., Struck M. M., Finkel B., Gerike E., Tischer A., Gassner M., Glück R. et al.( 1998;). Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines. . Vaccine 16: 298–304. [CrossRef] [PubMed]
    [Google Scholar]
  22. Singh M., Cattaneo R., Billeter M. A..( 1999;). A recombinant measles virus expressing hepatitis B virus surface antigen induces humoral immune responses in genetically modified mice. . J Virol 73: 4823–4828.[PubMed]
    [Google Scholar]
  23. Spielhofer P., Bächi T., Fehr T., Christiansen G., Cattaneo R., Kaelin K., Billeter M. A., Naim H. Y..( 1998;). Chimeric measles viruses with a foreign envelope. . J Virol 72: 2150–2159.[PubMed]
    [Google Scholar]
  24. Storch G. A..( 1998;). Humanized monoclonal antibody for prevention of respiratory syncytial virus infection. . Pediatrics 102: 648–651. [CrossRef] [PubMed]
    [Google Scholar]
  25. Tangy F., Naim H. Y..( 2005;). Live attenuated measles vaccine as a potential multivalent pediatric vaccination vector. . Viral Immunol 18: 317–326. [CrossRef] [PubMed]
    [Google Scholar]
  26. Throsby M., van den Brink E., Jongeneelen M., Poon L. L., Alard P., Cornelissen L., Bakker A., Cox F., van Deventer E. et al.( 2008;). Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. . PLoS One 3: e3942. [CrossRef] [PubMed]
    [Google Scholar]
  27. Wang Z., Hangartner L., Cornu T. I., Martin L. R., Zuniga A., Billeter M. A., Naim H. Y..( 2001;). Recombinant measles viruses expressing heterologous antigens of mumps and simian immunodeficiency viruses. . Vaccine 19: 2329–2336. [CrossRef] [PubMed]
    [Google Scholar]
  28. Welliver T. P., Garofalo R. P., Hosakote Y., Hintz K. H., Avendano L., Sanchez K., Velozo L., Jafri H., Chavez-Bueno S. et al.( 2007;). Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. . J Infect Dis 195: 1126–1136. [CrossRef] [PubMed]
    [Google Scholar]
  29. Widjojoatmodjo M. N., Bogaert L., Meek B., Zahn R., Vellinga J., Custers J., Serroyen J., Radošević K., Schuitemaker H..( 2015;). Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats. . Vaccine 33: 5406–5414. [CrossRef] [PubMed]
    [Google Scholar]
  30. Wu H., Pfarr D. S., Johnson S., Brewah Y. A., Woods R. M., Patel N. K., White W. I., Young J. F., Kiener P. A..( 2007;). Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. . J Mol Biol 368: 652–665. [CrossRef] [PubMed]
    [Google Scholar]
  31. Yamaji Y., Nakayama T..( 2014;). Recombinant measles viruses expressing respiratory syncytial virus proteins induced virus-specific CTL responses in cotton rats. . Vaccine 32: 4529–4536. [CrossRef] [PubMed]
    [Google Scholar]
  32. Zuniga A., Liniger M., Morin T. N., Marty R. R., Wiegand M., Ilter O., Weibel S., Billeter M. A., Knuchel M. C. et al.( 2013;). Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector. . Hum Vaccin Immunother 9: 607–613. [CrossRef] [PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.000523
Loading
/content/journal/jgv/10.1099/jgv.0.000523
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error